HTPEP 001
Alternative Names: HTPEP-001Latest Information Update: 02 Jan 2025
At a glance
- Originator Chengdu Huitai Biomedicine Co
- Class Antifibrotics; Antineoplastics; Peptides
- Mechanism of Action Thrombospondin 1 antagonists; Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Interstitial lung diseases
- No development reported Cancer
Most Recent Events
- 19 Dec 2024 Adverse events data from a phase-I clinical trials in Interstitial lung diseases (In volunteers)(Inhalation) released by Chengdu Huitai Biomedicine (Chengdu Huitai Biomedicine pipeline, Decmeber 2024)
- 19 Dec 2024 Preclinical development in Interstitial lung diseases is underway in China (Inhalation, Aerosol) (Chengdu Huitai Biomedicine pipeline, December 2024)
- 10 Jul 2024 Phase-I clinical trials in Interstitial lung diseases (In volunteers) in China (Inhalation) (CTR20241874)